Nananda Col

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1008267/nananda-col-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

5,050 26 66 g-index

65 papers 5,689 4.6 5.06 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
65	Efficacy of a patient decision aid for improving person-centered decision-making by older adults with obstructive sleep apnea. <i>Journal of Clinical Sleep Medicine</i> , 2021 , 17, 121-128	3.1	4
64	Improving patient-provider communication about chronic pain: development and feasibility testing of a shared decision-making tool. <i>BMC Medical Informatics and Decision Making</i> , 2020 , 20, 267	3.6	4
63	Development of a Program Promoting Person-Centered Care of Older Adults with Sleep Apnea. Journal of the American Geriatrics Society, 2019 , 67, 2204-2207	5.6	1
62	A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319879134	1.5	1
61	Changing PatientsTTreatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2018 , 9, 803-814	3.6	3
60	Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. <i>Medical Decision Making</i> , 2018 , 38, 44-55	2.5	25
59	Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018 , 20, 260-267	2.3	5
58	Should We Use the IMPACT-Model for the Outcome Prognostication of TBI Patients? A Qualitative Study Assessing PhysiciansTPerceptions. <i>MDM Policy and Practice</i> , 2018 , 3, 2381468318757987	1.5	7
57	Impact and Feasibility of Personalized Decision Support for Older Patients with Diabetes: A Pilot Randomized Trial. <i>Medical Decision Making</i> , 2017 , 37, 611-617	2.5	6
56	Patient-Provider Communication With Older Adults About Sleep Apnea Diagnosis and Treatment. <i>Behavioral Sleep Medicine</i> , 2017 , 15, 423-437	4.2	3
55	Patient-Reported Usability of Positive Airway Pressure Equipment Is Associated With Adherence in Older Adults. <i>Sleep</i> , 2017 , 40,	1.1	3
54	What Families Need and Physicians Deliver: Contrasting Communication Preferences Between Surrogate Decision-Makers and Physicians During Outcome Prognostication in Critically Ill TBI Patients. <i>Neurocritical Care</i> , 2017 , 27, 154-162	3.3	34
53	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 185-190	4.4	13
52	Design Features of Explicit Values Clarification Methods: A Systematic Review. <i>Medical Decision Making</i> , 2016 , 36, 453-71	2.5	72
51	Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict. <i>BMC Health Services Research</i> , 2016 , 16, 10	2.9	36
50	Perceived Effectiveness, Self-efficacy, and Social Support for Oral Appliance Therapy Among Older Veterans With Obstructive Sleep Apnea. <i>Clinical Therapeutics</i> , 2016 , 38, 2407-2415	3.5	8
49	Effects of Design Features of Explicit Values Clarification Methods: A Systematic Review. <i>Medical Decision Making</i> , 2016 , 36, 760-76	2.5	37

(2009-2015)

48	Decision Aids and Shared Decision-Making in Neurocritical Care: An Unmet Need in Our NeuroICUs. <i>Neurocritical Care</i> , 2015 , 23, 127-30	3.3	32
47	Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2015 , 31, 226	1-72	12
46	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 609-16	4.4	16
45	Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone. <i>Patient Preference and Adherence</i> , 2015 , 9, 609-17	2.4	16
44	Consumers and Clinical Decision Support 2014 , 741-769		2
43	Clarifying values: an updated review. <i>BMC Medical Informatics and Decision Making</i> , 2013 , 13 Suppl 2, S8	3.6	156
42	Balancing the presentation of information and options in patient decision aids: an updated review. BMC Medical Informatics and Decision Making, 2013 , 13 Suppl 2, S6	3.6	54
41	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2942-62	2.2	230
40	Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. <i>BMC Womens Health</i> , 2012 , 12, 1	2.9	31
39	Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 639-46	4.4	156
38	Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. Breast Journal, 2012 , 18, 299-302	1.2	O
37	Bisphosphonates and breast cancer prevention. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 14	4 - 50	15
36	Bisphosphonates and breast cancer incidence and recurrence. <i>Breast Disease</i> , 2011 , 33, 93-101	1.6	14
35	Interprofessional education about shared decision making for patients in primary care settings. Journal of Interprofessional Care, 2011 , 25, 409-15	2.7	22
34	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3235-58	2.2	223
33	Measuring the impact of menopausal symptoms on quality of life: methodological considerations. <i>Menopause</i> , 2009 , 16, 843-5	2.5	8
32	Duration of vasomotor symptoms in middle-aged women: a longitudinal study. <i>Menopause</i> , 2009 , 16, 453-7	2.5	97
31	Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). <i>PLoS ONE</i> , 2009 , 4, e4705	3.7	291

30	Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1331-2; author reply 132-3	9.7	1
29	Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. <i>Menopause</i> , 2008 , 15, 804-9	2.5	3
28	Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. <i>Journal of General Internal Medicine</i> , 2008 , 23, 1507-13	4	150
27	A latent class typology of young women smokers. <i>Addiction</i> , 2007 , 102, 1310-9	4.6	31
26	Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling. <i>Journal of Cancer Education</i> , 2007 , 22, 10-4	1.8	5
25	Do patient decision aids meet effectiveness criteria of the international patient decision aid standards collaboration? A systematic review and meta-analysis. <i>Medical Decision Making</i> , 2007 , 27, 554	- 7 45	196
24	Communicating the uncertainty of harms and benefits of medical interventions. <i>Medical Decision Making</i> , 2007 , 27, 681-95	2.5	237
23	Can computerized decision support help patients make complex treatment decisions? A randomized controlled trial of an individualized menopause decision aid. <i>Medical Decision Making</i> , 2007 , 27, 585-98	2.5	23
22	Using Internet technologies to improve and simplify counseling about menopause: the WISDOM website. <i>Maturitas</i> , 2007 , 57, 95-9	5	6
21	Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?. <i>Drugs</i> , 2007 , 67, 2311-21	12.1	14
20	Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. <i>Clinical Breast Cancer</i> , 2006 , 6 Suppl 2, S58-64	3	23
19	The pitfalls of non-evidence-based guidelines. <i>Menopause</i> , 2006 , 13, 334-7	2.5	1
18	Commentarysurgical decisions after breast cancer: can patients be too involved in decision making?. <i>Health Services Research</i> , 2005 , 40, 769-79	3.4	8
17	Internet use among community college students: implications in designing healthcare interventions. <i>Journal of American College Health</i> , 2004 , 52, 197-202	2.2	63
16	Subclinical thyroid disease: clinical applications. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 239-43	27.4	106
15	Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 228-38	27.4	1163
14	Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004 , 363, 410-1	40	20
13	The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience?. <i>Annals of Internal Medicine</i> , 2003 , 139, 923-9	8	36

LIST OF PUBLICATIONS

12	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003 , 30, 776-88	5.5	24
11	Meta-analysis of vascular and neoplastic events associated with tamoxifen. <i>Journal of General Internal Medicine</i> , 2003 , 18, 937-47	4	286
10	Estimating hip fracture morbidity, mortality and costs. <i>Journal of the American Geriatrics Society</i> , 2003 , 51, 364-70	5.6	612
9	The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant?. <i>Medical Decision Making</i> , 2003 , 23, 441-8	2.5	11
8	American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3328-43	2.2	166
7	Women Like Me. <i>Journal of Psychosocial Oncology</i> , 2002 , 20, 39-56	2.8	20
6	Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. <i>Medical Decision Making</i> , 2002 , 22, 386-93	2.5	8
5	Hormone replacement therapy after diagnosis of breast cancer did not increase breast cancer recurrence. <i>Evidence-Based Obstetrics and Gynecology</i> , 2002 , 4, 94-95		
4	The health care information directive. BMC Medical Informatics and Decision Making, 2001, 1, 1	3.6	10
3	Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2357-63	2.2	106
2	Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. <i>American Heart Journal</i> , 1996 , 131, 43-50	4.9	59
1	Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. <i>American Journal of Cardiology</i> , 1994 , 73, 149-57	3	25